Measles-Mumps-Rubella Vaccine
Phase 3Vaccine
Measles-Mumps-Rubella Vaccine is one of 23 biologic programs targeting Allergy. It is currently in Phase 3.
2
Indications
8
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
29 competitors in Allergy
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Flagyl
DDePuy Orthopaedics
Approved
Potassium Citrate
MMission Pharmacal
Approved
Levaquin
WWim Janssens
Approved
Achromycin V
WWyeth-Lederle Vaccines
Approved
Allegra
CChattem
Approved
Claritin
PPerrigo Company
Approved
Lastacaft
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Japanese encephalitis2 trials
Rotavirus Vaccine1 trial
The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine
Unknown status·SSichuan Center for Disease Control and Prevention·Phase 4·NCT02153866·2,800 enrolled
Immunization1 trial
Allergy1 trial
2 more indications
MMR Vaccine1 trial
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Completed·—·N/A·NCT04428359·66 enrolled
Cryotherapy1 trial
Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts
Completed·—·Phase 4·NCT03183765·48 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details